Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHENERFIN phase 3 study of sonlicromanol in adults with m.3243A>G primary mitochondrial disease
NL-OMON60979Phase 3Recruiting
- Sponsor
- Khondrion
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of sonlicromanol in Mitochondriopathy, sponsored by Khondrion. Primary endpoints: Change from baseline at Week 52 in Neuro-QoL Fatigue SF v1 score and Change from baseline at Week 52 in duration of the 5 Times Sit-to-Stand Test. Started Mar 2026; status: recruiting.
02
Drugs
sonlicromanol
03
Conditions
Mitochondriopathy
Beyond the preview
Go deeper on NL-OMON60979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60979.